{"id":"NCT00744627","sponsor":"Takeda","briefTitle":"Efficacy and Safety of Vortioxetine (Lu AA21004) for Treatment of Generalized Anxiety Disorder in Adults.","officialTitle":"A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Fixed-Dose Study Comparing the Efficacy and Safety of a Single Dose of Lu AA21004 in Acute Treatment of Adults With Generalized Anxiety Disorder","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-09","primaryCompletion":"2009-07","completion":"2009-07","firstPosted":"2008-09-01","resultsPosted":"2014-03-03","lastUpdate":"2014-03-03"},"enrollment":301,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Generalized Anxiety Disorder"],"interventions":[{"type":"DRUG","name":"Vortioxetine","otherNames":["Lu AA21004","BrintellixÂ®"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Vortioxetine 5 mg","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the efficacy and safety of vortioxetine, once daily (QD), in adults with Generalized Anxiety Disorders.","primaryOutcome":{"measure":"Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8","timeFrame":"Baseline to Week 8","effectByArm":[{"arm":"Placebo","deltaMin":-10.49,"sd":0.697},{"arm":"Vortioxetine 5 mg","deltaMin":-14.3,"sd":0.695}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":18},"locations":{"siteCount":38,"countries":["Estonia","Germany","Latvia","Lithuania","Poland","Romania","Russia","Ukraine"]},"refs":{"pmids":["22898365","29081307"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":150},"commonTop":["Nausea","Headache","Dizziness","Dry mouth","Somnolence"]}}